TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Response rate (stable disease or better)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of the combination
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Sexual Functioning Questionnaire Total Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Complete Response (no Episodes of Nausea or Vomiting)
Endpoint domain: Adverse events/effects
Primary endpoint: Endoscopic recurrence of disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seroprevalence of antibodies anti-SARS Cov2 in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroprevalence of antibodies anti-SARS Cov2 in saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change of circulating tumor cell (CTC) count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Eye Mobility During Surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Periodontal Soft Tissue Healing Progress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: arachidonic acid-induced platelet aggregation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in plasma IL-6 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: COVID-19 disease progression by Week 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of Use of the Premie Pouch
Endpoint domain: Adverse events/effects
Primary endpoint: re-intubation
Endpoint domain: Adverse events/effects
Primary endpoint: Foot and Ankle Ability Measures
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: medical cost differential
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Visibility of the injected gel marker
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of pneumothoraxes
Endpoint domain: Adverse events/effects
Primary endpoint: Pathologic CR Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change From Baseline in Unstimulated Salivary Flow Rate (uSFR) at Week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Impression of Change Scale (GICS) at Week 4 Assessed by the Carer/Parent(s)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Occurrence of Treatment Emergent Adverse Events (TEAEs) Overall and Per Injection Cycle
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Spontaneous Bowel Movements (SBMs) Within 1 Week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Patients Attending Screening Appointment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: freedom from AF/AT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of patients with molecular response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients who remain in sustained treatment free remission, without molecular relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Surgical Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Area Under The Plasma Concentration-time Curve From 0 to 24 Hours (AUC0-24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preterm delivery less than 34 weeks
Endpoint domain: Mortality/survival
Primary endpoint: Life quality: Short-form 36
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Neurogenic Bladder Symptom Score Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: The King's Health Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Children's BMI Percentiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Feasibility of EIT Monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in MRS from SADS-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of Osteoporosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ctDNA methylation status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Requirement of postoperative analgesics for postoperative 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immediate postoperative pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative nociception score (surgical pleth index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steady-state Serum Concentration of Dalotuzumab at 336 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in behavior problems
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline in the left ventricular ejection fraction at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in the left ventricular end-systolic volume at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in the concentration of N-terminal pro-Brain Natriuretic Peptide at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Presence or lack of germs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Participants' retention rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Maximum Observed Drug Concentration in Plasma (Cmax) of Tedizolid Phosphate (Prodrug)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Reach Peak Plasma Concentration (Tmax) of Tedizolid Phosphate (Prodrug)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Time Curve (AUC) of Tedizolid Phosphate (Prodrug) From Time Zero to Last Detectable Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MSCT RV/LV Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: SCORing Atopic Dermatitis (SCORAD) index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prefrontal blood oxygen level dependent activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Total Number of Capsules Taken During Discontinuation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change from baseline concentration of biomarkers of systemic inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Costs of Intravenous Patient Controlled Analgesia (PCA)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Quality of retinal and/or corneal microscope integrated optical coherence tomography image capture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of change in ocular morphology before and after standard surgical steps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estimate of subretinal fluid volume before and after surgery for retinal detachment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in child anxiety symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in child anxiety levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in IPSS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: feasibility of web portal
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Good Toxicity Outcome
Endpoint domain: Adverse events/effects
Primary endpoint: Acute Rectal Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Infectious Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Epidural catheter migration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Suicidal Ideology (SI) Participants Who Agree to Receive a Safety Plan
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of Eligible Patients
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Satisfaction With Safety Planning
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of Subjects With a Target Wound Closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Sensitivity and specificity of CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of ESR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of synovial leukocyte counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of blood in the stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Physical activity and sedentary behaviour
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Delirium Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gross Motor Function Measure (GMFM)-88 item score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in PANSS-EC Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of GA101 in induction therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Weekly physical activity levels
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Weekly sitting time
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in endometrial thickness after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Onset of pregnancy
Endpoint domain: Life impact
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in Dual-Task Cost
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of participants with any RIC-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Complications of endotracheal intubation
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence rate of PAH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence rate of PAH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Log Likelihood Median Values of HCV RNA Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of health related physical fitness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change of CR/LT From Baseline at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neck or back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Center of Gravity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective Visual Vertical
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PFT improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fraction of Participants Who Can Receive Induction Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in patient-reported-outcome (PRO) survey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in modified Harris hip score (mHHS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Non arthritic hip score (NAHS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Testis Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prenatal depressive symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maximum recovery of the radioactive dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Pharmacokinetic profile of Dexmedetomidine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent Plasma Terminal Half-life (t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC TAU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of screened participants that are eligible and agree to participate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: time to return to active sport
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: 30-day emergency revisit or hospital admission for acute heart failure
Endpoint domain: Mortality/survival
Primary endpoint: cardiovascular mortality rate after discharge
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of Unacceptable Movement Under General Anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Acute Myocardial Infarction (AMI)
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of Acute on Chronic Liver Failure
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of Acute Kidney Failure (AKF)
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of Multiple Organ Dysfunction Syndrome (MODS)
Endpoint domain: Mortality/survival
Primary endpoint: Hematological toxicities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Difference in the mean number of aura attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Difference in the mean number of migraine headache days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Efficacy of antiseptic solutions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Glycopeptide signature of serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: days of use of the primary drug of abuse
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Adequate relief of symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Postoperative occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Progression-free survival at 4 months
Endpoint domain: Mortality/survival
Primary endpoint: Change in Disability Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Presence or Absence of peroneus tertius
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Foot Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence, causality, and severity of adverse experiences
Endpoint domain: Adverse events/effects
Primary endpoint: Local breast recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Recommended Phase 2 Dose of LY573636-Sodium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: BLS practical skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central Nervous System Vital Signs (CNSVS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Functional Assessment of Cancer Therapy-Cognitive
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Rate of gestational weight gain per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of women exceeding the Institute of Medicine's recommendation for rate of gestational weight gain per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Assessment of pain severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absences of swelling / fistulous tract
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ovulation Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: vascular inflammation of the carotid artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Maximum tolerated dose (MTD) as defined by toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: mean serum concentrations of insulin-like growth factor-1 (IGF-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: mean serum concentrations of growth hormone (GH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: difference in the aortic dimension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Complete blood picture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: 6-minute walk Distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breath-hold test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Borg Dyspnea Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with a progression to Lower Respiratory Tract Complication (LRTC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in RSV nasal viral load (via RT-qPCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Short time complication rate
Endpoint domain: Adverse events/effects
Primary endpoint: Repeated drainage frequency
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Receipt of reperfusion therapy within 12 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time to meet readiness-for-discharge criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Cardiorespiratory fitness assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LDL Aggregation susceptibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lowering total triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: EPA incorporation into LDL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of subjects with adverse events (AEs)/serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with abnormal blood pressure (BP) and pulse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of subjects with abnormal electrocardiogram (ECG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of subjects with abnormal clinical chemistry/hematology/urinalysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with abnormal physical examination results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Discontinued Due to an Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Meet the Markedly Abnormal Criteria for Neurological Assessment Measurements at Least Once Post Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in NRF2 target gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fracture and retention of the materials
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surface and marginal staining of the materials
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wear of the materials
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and severity of treatment emergent Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: AEs leading to discontinuation from Investigational Medicinal Product (IMP) or the study
Endpoint domain: Adverse events/effects
Primary endpoint: Percent Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: number of persons up to date with vaccinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of participants with atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes